Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
20063.7k citationsHagop Youssoufian, Eric K. Rowinsky et al.profile →
Paclitaxel (Taxol)
19951.6k citationsEric K. Rowinsky, Ross C. Donehowerprofile →
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
20091.4k citationsHagop Youssoufian, Eric K. Rowinsky et al.profile →
Taxol: A Novel Investigational Antimicrotubule Agent
1990895 citationsEric K. Rowinsky, Ross C. Donehower et al.JNCI Journal of the National Cancer Instituteprofile →
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
2004893 citationsLisa A. Hammond, Eric K. Rowinsky et al.Journal of Clinical Oncologyprofile →
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
2001830 citationsManuel Hidalgo, Lisa A. Hammond et al.Journal of Clinical Oncologyprofile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
2006794 citationsMark J. Ratain, Tim Eisen et al.Journal of Clinical Oncologyprofile →
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
2002646 citationsLisa A. Hammond, Eric K. Rowinsky et al.Journal of Clinical Oncologyprofile →
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
The Current Status of Camptothecin Analogues as Antitumor Agents
1993542 citationsEric K. Rowinsky, Ross C. Donehower et al.JNCI Journal of the National Cancer Instituteprofile →
Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)
2003524 citationsEric K. Rowinsky et al.Journal of Clinical Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Eric K. Rowinsky
Since
Specialization
Citations
This map shows the geographic impact of Eric K. Rowinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric K. Rowinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric K. Rowinsky more than expected).
Fields of papers citing papers by Eric K. Rowinsky
This network shows the impact of papers produced by Eric K. Rowinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric K. Rowinsky. The network helps show where Eric K. Rowinsky may publish in the future.
Co-authorship network of co-authors of Eric K. Rowinsky
This figure shows the co-authorship network connecting the top 25 collaborators of Eric K. Rowinsky.
A scholar is included among the top collaborators of Eric K. Rowinsky based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Eric K. Rowinsky. Eric K. Rowinsky is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Prewett, Marie, Rajiv Bassi, Hagop Youssoufian, Eric K. Rowinsky, & James R. Tonra. (2009). Abstract #2774: The fully human EGFR antibody IMC-11F8 significantly increases the antitumor effects of cisplatin+gemcitabine in human non-small cell lung cancer models. Cancer Research. 69. 2774–2774.3 indexed citations
Chiorean, Elena G., Christopher Sweeney, S. Savage, et al.. (2007). Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers. Molecular Cancer Therapeutics. 6.12 indexed citations
7.
LoRusso, Patricia, Michael A. Gordon, Evan Y. Yu, et al.. (2007). A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis. Molecular Cancer Therapeutics. 6.9 indexed citations
8.
Ratain, Mark J., Tim Eisen, Walter M. Stadler, et al.. (2006). Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(16). 2505–2512.794 indexed citations breakdown →
Ricart, Alejandro D., Anthony W. Tolcher, Quincy S. Chu, et al.. (2006). Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients (pts) with advanced malignancies. Cancer Research. 66. 685–685.3 indexed citations
Calvo, Emiliano, Andrew Goetz, Peter L. Bonate, et al.. (2005). Analysis of dose proportionality testing methods in phase I clinical trials of anticancer agents. Cancer Research. 65. 973–974.1 indexed citations
McGuire, William P. & Eric K. Rowinsky. (1995). Paclitaxel in cancer treatment. M. Dekker eBooks.37 indexed citations
19.
Noe, D A, Eric K. Rowinsky, L B Grochow, et al.. (1990). Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).. PubMed. 50(15). 4595–9.32 indexed citations
20.
Rowinsky, Eric K., et al.. (1987). Microtubule changes and cytotoxicity produced by taxol in human ovarian cell lines. 28. 423.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.